Back to Search
Start Over
Automation of ALK gene rearrangement testing with fluorescence in situ hybridization (FISH): a feasibility study.
- Source :
-
Experimental and molecular pathology [Exp Mol Pathol] 2015 Feb; Vol. 98 (1), pp. 113-8. Date of Electronic Publication: 2015 Jan 08. - Publication Year :
- 2015
-
Abstract
- In the past several years we have observed a significant increase in our understanding of molecular mechanisms that drive lung cancer. Specifically in the non-small cell lung cancer sub-types, ALK gene rearrangements represent a sub-group of tumors that are targetable by the tyrosine kinase inhibitor Crizotinib, resulting in significant reductions in tumor burden. Phase II and III clinical trials were performed using an ALK break-apart FISH probe kit, making FISH the gold standard for identifying ALK rearrangements in patients. FISH is often considered a labor and cost intensive molecular technique, and in this study we aimed to demonstrate feasibility for automation of ALK FISH testing, to improve laboratory workflow and ease of testing. This involved automation of the pre-treatment steps of the ALK assay using various protocols on the VP 2000 instrument, and facilitating automated scanning of the fluorescent FISH specimens for simplified enumeration on various backend scanning and analysis systems. The results indicated that ALK FISH can be automated. Significantly, both the Ikoniscope and BioView system of automated FISH scanning and analysis systems provided a robust analysis algorithm to define ALK rearrangements. In addition, the BioView system facilitated consultation of difficult cases via the internet.<br /> (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Subjects :
- Algorithms
Anaplastic Lymphoma Kinase
Automation
Carcinoma, Non-Small-Cell Lung drug therapy
Carcinoma, Non-Small-Cell Lung pathology
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Crizotinib
Feasibility Studies
Humans
Lung Neoplasms drug therapy
Lung Neoplasms pathology
Neoplasm Staging
Prognosis
Protein Kinase Inhibitors therapeutic use
Pyrazoles therapeutic use
Pyridines therapeutic use
Software
Carcinoma, Non-Small-Cell Lung genetics
Data Interpretation, Statistical
Gene Rearrangement
In Situ Hybridization, Fluorescence methods
Lung Neoplasms genetics
Receptor Protein-Tyrosine Kinases genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1096-0945
- Volume :
- 98
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Experimental and molecular pathology
- Publication Type :
- Academic Journal
- Accession number :
- 25576649
- Full Text :
- https://doi.org/10.1016/j.yexmp.2015.01.005